QS Research · Michael Burry's Scion Capital analyst template · 2006
CG Oncology, Inc. (CGON)
As of 2026-11-18 · 12/15 boxes filled from SEC filings and market data
Report price $78.94 (close 2026-11-17); latest close $79.47 (2026-11-20), +0.7% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -56% · upside -1%
The market is pricing CG Oncology at 984.33x EV/Sales on $6.2M of TTM revenue, a valuation that already assumes clinical and regulatory success rather than current sales. The call is PASS: the quality gate fails, with no evidenced moat, ROIC below WACC and a weak FCF yield. Downside is -55.9% to $34.84, from -30.0% sales at a compressed EV/Sales of 493.67x (today 984.33x). There is no base case: no comparable peer multiple sets one, no independent multiple (peer median or own history) was available, and a base at today's multiple is today's price by construction. Upside is 0.0% to $78.94, the analyst's own upside (no earnings change was given to price it). With only a downside and a flat upside, the risk/reward does not support a value purchase; this means not a value buy at this price, not a bad business.
Key numbers
- Share price: $79.47
- Market cap: $7.10B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $6.2M
- FCF yield: -2.7%
- Price / book: 7.17x
- Revenue growth (latest fiscal year): +254.7%
- ROIC (TTM): -1328.3%
- WACC: 11.4%
- Economic profit spread: -1339.7 pts
The 15 boxes
- ✓ 1. Long-form business notes
CG Oncology is a single-asset, pre-commercial biopharma: revenue was only $204,000 in FY2023, $1.1M in FY2024, $4.0M in FY2025 and $6.2M for the TTM to 2026-09-30, against operating losses widening from -$55.4M to -$264.7M over the same spans, so the business is funded by equity, not operations. The economic case rests on one intravesical oncolytic immunotherapy, cretostimogene, in BOND-003 Cohort C for high-risk BCG-unresponsive NMIBC (75.5% CR at any time in 46 of 110 patients, June 23, 2025 cutoff), with a BLA begun in Q4 2025 and expected to be completed in 2026. Between the FY2023 and latest 10-K the story moved from 'topline by end of 2024' to a filed BLA, a completed PIVOT-006 enrollment, three more CORE-008 cohorts, and the start of an in-house U.S. commercial build. Cash plus short-term investments rose from $8.3M + $179.4M at FY2023 to $28.2M + $956.2M at the TTM to 2026-09-30, with diluted shares at 88.13M.
- ✓ 2. Competitive advantage
No durable competitive advantage is demonstrated: CG Oncology is a single-asset Phase 3 developer with $6.2M TTM revenue against a $264.7M TTM operating loss and negative $187.3M TTM operating cash flow. Its only moat-like items are a regional Kissei license/supply arrangement and control of CMO Biovire, which is not profitable and was a new operating capability. It faces BCG and numerous larger oncology competitors with greater resources.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue was $1.604 million versus $1.666 million a year earlier, all of it Biovire contract manufacturing; license and collaboration revenue fell to zero. Cost of sales ($2.669 million, Q3 2026) exceeded that revenue, R&D jumped 41% to $39.221 million on CMC spend and headcount, and G&A was flat at $22.963 million, producing a $63.249 million operating loss and a $56.891 million net loss ($(0.64) per share). Cash and marketable securities were $984.5 million at September 30, 2026, funded partly by $391.4 million of ATM net proceeds in the nine months, and the release says that funds operations through 2029. The pipeline calendar is the guidance: PIVOT-006 topline in November 2026, 12-month data from two cohorts in December 2026, BLA completion in Q4 2026.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.